2021
KRAS‐Mutated, Estrogen Receptor‐Positive Low‐Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery
Kato S, McFall T, Takahashi K, Bamel K, Ikeda S, Eskander R, Plaxe S, Parker B, Stites E, Kurzrock R. KRAS‐Mutated, Estrogen Receptor‐Positive Low‐Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery. The Oncologist 2021, 26: e530-e536. PMID: 33528846, PMCID: PMC8018312, DOI: 10.1002/onco.13702.Peer-Reviewed Original ResearchConceptsMEK inhibitorsMechanism of actionOvarian cancerAromatase inhibitorsEstrogen modulationKRAS-mutantLow-grade serous ovarian cancerCombination of trametinibEstrogen receptor-positiveSerous ovarian cancerPrecision medicine strategiesPI3K inhibitorsReceptor-positiveCombination therapyEstrogen depletionTamoxifenTrametinibAgonist effectsIn vitro investigationLetrozoleEstrogenIn vitro experimentsMedicine strategiesMEKExceptional response
2020
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
Kato S, Kim K, Lim H, Boichard A, Nikanjam M, Weihe E, Kuo D, Eskander R, Goodman A, Galanina N, Fanta P, Schwab R, Shatsky R, Plaxe S, Sharabi A, Stites E, Adashek J, Okamura R, Lee S, Lippman S, Sicklick J, Kurzrock R. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nature Communications 2020, 11: 4965. PMID: 33009371, PMCID: PMC7532150, DOI: 10.1038/s41467-020-18613-3.Peer-Reviewed Original ResearchConceptsMolecular tumor boardOverall survivalTumor boardNext-generation sequencingReviewed patient characteristicsResistant to monotherapyProgression-freeOncological outcomesRemission rateChoice regimenGenomic alterationsPatient characteristicsRecommended drugsMolecular findingsPatientsTherapyMaster protocolCancer targetPhysician-directedPFSPrecision strategySurvivalDrugMedication accessOutcomes
2012
Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing
Liang W, Craig D, Carpten J, Borad M, Demeure M, Weiss G, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer J, Legendre C, Posner R, Hostetter G, Baker A, Egan J, Han H, Lake D, Stites E, Ramanathan R, Fonseca R, Stewart A, Von Hoff D. Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing. PLOS ONE 2012, 7: e43192. PMID: 23071490, PMCID: PMC3468610, DOI: 10.1371/journal.pone.0043192.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaBase SequenceBRCA2 ProteinDNA RepairFemaleGene DosageGenome, HumanHigh-Throughput Nucleotide SequencingHumansMaleMetabolic Networks and PathwaysPancreatic NeoplasmsProto-Oncogene ProteinsProto-Oncogene Proteins c-mycProto-Oncogene Proteins p21(ras)Ras ProteinsSequence Analysis, RNATranscriptomeTumor Suppressor Protein p53ConceptsPancreatic adenocarcinoma patientsNext generation sequencingPancreatic adenocarcinomaGeneration sequencingSomatic eventsGenome-wide characterizationChromosomal copy number variantsCopy number variantsImproved therapeutic selectivityTumor suppressive pathwaysPancreatic adenocarcinoma tumorigenesisTumor-stroma interactionsKRAS signaling pathwaySequence dataTranscriptomic informationTumor/normal samplesEvaluate expression changesTranslocation eventsMultiple genesPoint mutationsRNA sequencingMapped readsPatient tumorsAdenocarcinoma patientsPathway analysis